Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
k4FzuwbjKXbAv49k
